Do RANKL inhibitors (denosumab) affect inflammation and immunity?

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Osteoporosis International

• Publication date

  2011-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00198-010-1326-yPMID 20571772
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

  2011cited by this paper
• Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock‐In Mice That Express Chimeric (Murine/Human) RANKL

  2009influential reference
• RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFα or anti-IL-1 therapies

  2009cited by this paper
• 2LBA Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study

  2009cited by this paper
• One Year of Transgenic Overexpression of Osteoprotegerin in Rats Suppressed Bone Resorption and Increased Vertebral Bone Volume, Density, and Strength

  2009cited by this paper
• Denosumab in men receiving androgen-deprivation therapy for prostate cancer.

  2009cited by this paper
• Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

  2009cited by this paper
• 20LBA A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma

  2009cited by this paper
• The RANKL signaling axis is sufficient to elicit ductal side-branching and alveologenesis in the mammary gland of the virgin mouse.

  2009cited by this paper
• Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations.

  2008cited by this paper
• Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade

  2008cited by this paper
• Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

  2008cited by this paper
• Epidermal Receptor Activator of NF-κB Ligand Controls Langerhans Cells Numbers and Proliferation12

  2008cited by this paper
• Denosumab and the Treatment of Rheumatoid Arthritis: In an Occupied Field, Where Will a RANKL Inhibitor Fit In?

  2008cited by this paper
• Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.

  2008cited by this paper
• Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.

  2008cited by this paper
• The BLyS Family: Toward a Molecular Understanding of B Cell Homeostasis

  2008cited by this paper
• Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.

  2008cited by this paper
• Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

  2008cited by this paper
• Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial.

  2008influential reference
• Further Insights in the Mechanisms of Interleukin‐1β Stimulation of Osteoprotegerin in Osteoblast‐Like Cells

  2007cited by this paper
• Continuous RANKL Inhibition in Osteoprotegerin Transgenic Mice and Rats Suppresses Bone Resorption without Impairing Lymphorganogenesis or Functional Immune Responses1

  2007influential reference
• Human rheumatoid synovial fibroblasts promote osteoclastogenic activity by activating RANKL via TLR-2 and TLR-4 activation.

  2007cited by this paper
• Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL

  2007influential reference
• Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

  2007cited by this paper
• Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis

  2007cited by this paper
• Cytokines in the pathogenesis of rheumatoid arthritis

  2007cited by this paper
• Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection.

  2007cited by this paper
• B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo.

  2007cited by this paper
• Receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) increases vascular permeability: impaired permeability and angiogenesis in eNOS-deficient mice.

  2007cited by this paper
• RANKL-RANK signaling in osteoclastogenesis and bone disease.

  2006cited by this paper
• Receptor Activator of NF-κB Ligand and Osteoprotegerin Regulate Proinflammatory Cytokine Production in Mice1

  2006cited by this paper
• Denosumab in postmenopausal women with low bone mineral density.

  2006cited by this paper
• Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells

  2006cited by this paper
• RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production.

  2006cited by this paper
• Infections associated with tumor necrosis factor-alpha antagonists.

  2005cited by this paper
• The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis

  2005cited by this paper
• Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study.

  2005cited by this paper
• Infections Associated With Tumor Necrosis Factor-α Antagonists

  2005cited by this paper
• Rheumatic diseases: the effects of inflammation on bone

  2005cited by this paper
• Infections associated with tumor necrosis factor-alpha antagonists.

  2005cited by this paper
• Contribution of transmembrane tumor necrosis factor to host defense against Mycobacterium bovis bacillus Calmette-guerin and Mycobacterium tuberculosis infections.

  2005cited by this paper
• Class switch recombination in B lymphopoiesis: a potential pathway for B cell autoimmunity.

  2004cited by this paper
• A Novel in Vivo Role for Osteoprotegerin Ligand in Activation of Monocyte Effector Function and Inflammatory Response*

  2004influential reference
• Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.

  2004cited by this paper
• CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin

  2004cited by this paper
• A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease.

  2004cited by this paper
• Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.

  2004cited by this paper
• Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.

  2003cited by this paper
• TRANCE-RANK Costimulation is Required for IL-12 Production and the Initiation of a Th1-Type Response to Leishmania major Infection in CD40L-Deficient Mice 1

  2003cited by this paper
• Regulatory effects of osteoprotegerin on cellular and humoral immune responses.

  2003influential reference
• Functional Genomic Analysis of Remyelination Reveals Importance of Inflammation in Oligodendrocyte Regeneration

  2003cited by this paper
• エストロゲンの欠乏は,インターフェロン‐γ誘導性クラスIIトランスアクチベーターを介するT細胞増殖と寿命の上昇により骨消失を誘導する

  2003cited by this paper
• Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin.

  2003cited by this paper
• Organogenesis of lymphoid tissues

  2003cited by this paper
• Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-γ-induced class II transactivator

  2003cited by this paper
• Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.

  2003cited by this paper
• High prevalence of osteoporotic vertebral fractures in patients with Crohn’s disease

  2002cited by this paper
• Suppression of antibody production by TNF-related apoptosis-inducing ligand (TRAIL).

  2002cited by this paper
• Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.

  2002cited by this paper
• TNF Regulates Chemokine Induction Essential for Cell Recruitment, Granuloma Formation, and Clearance of Mycobacterial Infection1

  2002cited by this paper
• Evolution of IgM, IgE and IgG1–4 antibody responses in early childhood monitored with recombinant allergen components: implications for class switch mechanisms

  2002cited by this paper
• RANK-L and RANK: T cells, bone loss, and mammalian evolution.

  2002cited by this paper
• Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin.

  2002cited by this paper
• Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients.

  2001cited by this paper
• TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis.

  2001cited by this paper
• Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

  2001cited by this paper
• Osteoprotegerin, a Crucial Regulator of Bone Metabolism, Also Regulates B Cell Development and Function1

  2001influential reference
• Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

  2001cited by this paper
• Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis.

  2000cited by this paper
• Trance, a Tumor Necrosis Factor Family Member, Enhances the Longevity and Adjuvant Properties of Dendritic Cells in Vivo

  2000influential reference
• Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines.

  2000cited by this paper
• T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma.

  2000cited by this paper
• Regulation of Peripheral Lymph Node Genesis by the Tumor Necrosis Factor Family Member Trance

  2000cited by this paper
• TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling.

  1999cited by this paper
• RANK is essential for osteoclast and lymph node development.

  1999influential reference
• TRANCE, a Tumor Necrosis Factor Family Member Critical for CD40 Ligand–independent T Helper Cell Activation

  1999cited by this paper
• OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

  1999influential reference
• Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand

  1999cited by this paper
• Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand

  1999cited by this paper
• Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

  1999cited by this paper
• A novel role of IL-15 in the development of osteoclasts : inability to replace its activity with IL-2

  1999cited by this paper
• TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells.

  1999cited by this paper
• Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

  1999cited by this paper
• Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.

  1999cited by this paper
• IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis.

  1999cited by this paper
• Severe osteopetrosis, defective interleukin‐1 signalling and lymph node organogenesis in TRAF6‐deficient mice

  1999cited by this paper
• osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.

  1998cited by this paper
• Dendritic cells and the control of immunity

  1998cited by this paper
• Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

  1998cited by this paper
• Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.

  1998cited by this paper
• Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

  1998cited by this paper
• The lymphotoxin beta receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues.

  1998cited by this paper
• A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

  1997cited by this paper
• Distinct Roles in Lymphoid Organogenesis for Lymphotoxins α and β Revealed in Lymphotoxin β–Deficient Mice

  1997cited by this paper
• Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in lymphotoxin beta-deficient mice.

  1997cited by this paper
• DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition.

  1997cited by this paper
• A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

  1997cited by this paper
• Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.

  1997cited by this paper
• TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell–specific Survival Factor

  1997influential reference

• Manejo farmacológico de la pérdida ósea en pacientes con espondilodiscitis. Revisión sistemática

  2025cites this paper
• Mechanisms of osteoclast activation in inflammatory bone loss in rheumatoid arthritis

  2025cites this paper
• Treatment of myeloma bone disease: When, how often, and for how long?

  2025cites this paper
• Inflammatory Bridges: Interconnections Between Alzheimer’s Disease and Bone Health

  2025cites this paper
• Differential sclerostin secretion by zoledronic acid and an Anti-RANKL antibody in the tibia of an ovariectomized mouse model

  2025cites this paper
• Sophoraflavanone G Inhibits RANKL-Induced Osteoclastogenesis via MAPK/NF-κB Signaling Pathway

  2024cites this paper
• Cancer risk in patients treated with denosumab compared with alendronate: A population-based cohort study.

  2024cites this paper
• Effectiveness and safety of denosumab on osteoporosis treatment in kidney transplant recipients.

  2024cites this paper
• Peptide discovery across the spectrum of neuroinflammation; microglia and astrocyte phenotypical targeting, mediation, and mechanistic understanding

  2024cites this paper
• Administration of low intensity vibration and a RANKL inhibitor, alone or in combination, reduces bone loss after spinal cord injury-induced immobilization in rats

  2024cites this paper
• Siglec-15 as a potential molecule involved in osteoclast differentiation and bone metabolism

  2024cites this paper
• Synergistic effect between denosumab and immune checkpoint inhibitors (ICI)? A retrospective study of 268 patients with ICI and bone metastases

  2024cites this paper
• Synthesis and Antiosteoporotic Characterization of Diselenyl Maleimides: Discovery of a Potent Agent for the Treatment of Osteoporosis by Targeting RANKL.

  2024cites this paper
• The use of denosumab in osteoporosis – an update on efficacy and drug safety

  2024cites this paper
• Biologic Antiresorptive: Denosumab

  2023cites this paper
• RANKL/RANK is required for cytokine-induced beta cell death; osteoprotegerin, a RANKL inhibitor, reverses rodent type 1 diabetes

  2023cites this paper
• Efficacy and safety of COVID-19 vaccines for patients with spinal tumors receiving denosumab treatment: An initial real−clinical experience study

  2023cites this paper
• Phase I, Randomized, Placebo-Controlled, Dose-Escalation Study of GB223, a Fully-Humanized Monoclonal Antibody to RANKL, in Healthy Chinese Adults

  2023cites this paper
• Influence of antiresorptive/antiangiogenic therapy on the extension of experimentally induced peri-implantitis lesions

  2023cites this paper
• Current therapies and future prospective for locally aggressive mesenchymal tumors

  2023cites this paper
• Clinical impact on dental implant survival in patients taking antiresorptive medications: A systematic review and meta-analysis.

  2023cites this paper
• Mini Review Therapeutic Strategies Targeting for Biofilm and Bone Infections

  2022cites this paper
• Epigenetic quantification of immunosenescent CD8+ TEMRA cells in human blood

  2022cites this paper
• Indigenous microbiota protects development of medication-related osteonecrosis induced by periapical disease in mice

  2022cites this paper
• Malignant Transformation of Giant Cell Tumour of Bone: A Review of Literature and the Experience of a Referral Centre

  2022cites this paper
• Identification of a binding site on soluble RANKL that can be targeted to inhibit soluble RANK-RANKL interactions and treat osteoporosis

  2022cites this paper
• Roles of the RANKL–RANK Axis in Immunity—Implications for Pathogenesis and Treatment of Bone Metastasis

  2022cites this paper
• The Roadmap of RANKL/RANK Pathway in Cancer

  2021cites this paper
• Denosumab in chronic kidney disease: a narrative review of treatment efficacy and safety

  2021cites this paper
• Pharyngeal spreading of peri-implant infections under antiresorptive/antiangiogenic therapy

  2021cites this paper
• Molecular Targeted Therapy for the Bone Loss Secondary to Pyogenic Spondylodiscitis Using Medications for Osteoporosis: A Literature Review

  2021cites this paper
• Effects of Selected Non-biological and Biological Disease-Modifying Anti-rheumatic Drugs, and mRNA Vaccines on Mononuclear Phagocyte System

  2021cites this paper
• Osteoporosis associated with gastrointestinal disorders: celiac and inflammatory bowel diseases

  2021cites this paper
• Adverse events associated with bone-directed therapies in patients with cancer.

  2021cites this paper
• Multicentric carpotarsal osteolysis syndrome (MCTO) with generalized high bone turnover and high serum RANKL: Response to denosumab

  2021cites this paper
• Regulation of TNF-Induced Osteoclast Differentiation

  2021cites this paper
• EC GASTROENTEROLOGY AND DIGESTIVE SYSTEM EC GASTROENTEROLOGY AND DIGESTIVE SYSTEM Mini Review Review: Epidemiology and Pathophysiology of Osteoporosis in Inflammatory Bowel Disease

  2021cites this paper
• Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review

  2021cites this paper
• Secondary Malignancy in Giant Cell Tumor: A Single-Center Study

  2021cites this paper
• Secondary Osteoporosis

  2021cites this paper
• [Current status and perspectives in the development of therapeutic agents targeting post-ischemic inflammation in the acute stage of stroke].

  2020cites this paper
• Pathophysiology and Epidemiology of Osteoporosis

  2020cites this paper
• Role of dendritic cell‐mediated immune response in oral homeostasis: A new mechanism of osteonecrosis of the jaw

  2020cites this paper
• Bone loss in patients with inflammatory bowel disease: cause, detection and treatment

  2020cites this paper
• The safety profile of denosumab in oncology beyond the safety of denosumab as an anti-osteoporotic agent: still more to learn

  2020cites this paper
• RANK/RANKL/OPG Signaling in the Brain: A Systematic Review of the Literature

  2020cites this paper
• Denosumab is not associated with risk of malignancy: systematic review and meta-analysis of randomized controlled trials

  2020cites this paper
• Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw

  2020cites this paper
• The Role of the RANKL/RANK Axis in the Prevention and Treatment of Breast Cancer with Immune Checkpoint Inhibitors and Anti-RANKL

  2020cites this paper
• Denosumab in Giant Cell Tumor of Bone: Current Status and Pitfalls

  2020cites this paper
• Inhibition of the RANKL with denosumab has no effect on circulating markers of atherosclerosis in women with postmenopausal osteoporosis: a pilot study

  2020cites this paper
• Gene Expression Profile and Acute Gene Expression Response to Sclerostin Inhibition in Osteogenesis Imperfecta Bone

  2020cites this paper
• Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy

  2020cites this paper
• Role of Bone Targeting Agents in the Prevention of Bone Metastases from Breast Cancer

  2020cites this paper
• Combining immune checkpoint inhibitors with denosumab: a new era in repurposing denosumab in oncology?

  2020cites this paper
• Risk factors for medication-related osteonecrosis of the jaws: a case-control study in Queensland, Australia

  2019cites this paper
• Predictive Value of Osteoprotegerin and Neutrophil Gelatinase-associated Lipocalin on Multiple Organ Failure in Multiple Trauma

  2019cites this paper
• Perspective on skeletal health in inflammatory bowel disease

  2019cites this paper
• Treatment Effects of Bisphosphonates and Denosumab on Survival and Refracture from Real-World Data of Hip-Fractured Patients

  2019cites this paper
• Full blood counts are not predictive of the risk of medication-related osteonecrosis of the jaws: a case-control study.

  2019cites this paper
• Osteoclast Signal Transduction Pathways: The RANKL/RANK System

  2019cites this paper
• Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review

  2019cites this paper
• Loss of RANKL in osteocytes dramatically increases cancellous bone mass in the osteogenesis imperfecta mouse (oim)

  2018cites this paper
• Therapeutic Effects of Systemic Administration of the Novel RANKL-Modified Peptide, MHP1, for Ischemic Stroke in Mice

  2018cites this paper
• Development of a novel RANKL-based peptide, microglial healing peptide1-AcN (MHP1-AcN), for treatment of ischemic stroke

  2018cites this paper
• RANKL Triggers Treg-Mediated Immunoregulation in Inflammatory Osteolysis

  2018cites this paper
• Denosumab‐induced cutaneous hypersensitivity reaction with distinct clinical and histopathologic findings

  2018cites this paper
• The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review.

  2018cites this paper
• The triptolide‐induced apoptosis of osteoclast precursor by degradation of cIAP2 and treatment of rheumatoid arthritis of TNF‐transgenic mice

  2018cites this paper
• Cellular interactions underpinning the immunomodulatory action of mesenchymal stromal cells in models of liver transplant injury

  2018cites this paper
• Osteogenesis imperfecta and therapeutics.

  2018cites this paper
• The Role of MicroRNA‐143‐5p in the Differentiation of Dental Pulp Stem Cells into Odontoblasts by Targeting Runx2 via the OPG/RANKL Signaling Pathway

  2018cites this paper
• Effects of constrained dynamic loading, CKIP‑1 gene knockout and combination stimulations on bone loss caused by mechanical unloading.

  2018cites this paper
• Up-regulated expression of CD147 gene in malignant bone tumor and the possible induction mechanism during osteoclast formation

  2018cites this paper
• Removal of Pre-Existing Periodontal Inflammatory Condition before Tooth Extraction Ameliorates Medication-Related Osteonecrosis of the Jaw-Like Lesion in Mice.

  2018cites this paper
• Biologic therapies and bone loss in rheumatoid arthritis

  2017cites this paper
• Anti-Tumour Treatment The anti-tumor effect of RANKL inhibition in malignant solid tumors – A systematic review

  2017influential citation
• Comorbidity and Patient-Reported Outcomes

  2017cites this paper
• Infections in De Novo Kidney Transplant Recipients Treated With the RANKL Inhibitor Denosumab

  2017cites this paper
• Denosumab for the treatment of osteoporosis

  2017cites this paper
• Beyond Antibodies: B Cells and the OPG/RANK-RANKL Pathway in Health, Non-HIV Disease and HIV-Induced Bone Loss

  2017cites this paper
• Macrophages and skeletal health

  2017cites this paper
• Proton pump inhibitors in liver cirrhosis: a review of benefits and harms

  2017cites this paper
• Osteonecrosis of the Jaw—a Bone Site-Specific Effect of Bisphosphonates

  2016cites this paper
• A Novel Therapeutic Peptide as a Partial Agonist of RANKL in Ischemic Stroke

  2016cites this paper
• RANK/RANKL/OPG pathway: genetic association with history of ischemic stroke in Italian population.

  2016cites this paper
• Current Controversies on the Pathogenesis of Medication-Related Osteonecrosis of the Jaw

  2016cites this paper
• Effect of Twice‐Yearly Denosumab on Prevention of Bone Mineral Density Loss in De Novo Kidney Transplant Recipients: A Randomized Controlled Trial

  2016cites this paper
• Molecular Mechanisms of Bone Metastasis.

  2016cites this paper
• The challenging interplay between rheumatoid arthritis, ageing and comorbidities

  2016cites this paper
• Alopecia areata after denosumab treatment for osteoporosis

  2016cites this paper
• Update on Inflammatory Biomarkers and Treatments in Ischemic Stroke

  2016cites this paper
• Effects of denosumab on peripheral lymphocyte subpopulations

  2016cites this paper
• Long-Term Efficacy and Safety of Treatments for Osteoporosis

  2016cites this paper
• Other Safety Concerns

  2016cites this paper
• Osteoimmunological Aspects of Periodontal Diseases

  2016cites this paper
• 7. Novel and current approaches to dietary and non-dietary bone metabolism regulation

  2016cites this paper
• How Long to Treat with Denosumab

  2015cites this paper
• TNF Induction of NF-κB RelB Enhances RANKL-Induced Osteoclastogenesis by Promoting Inflammatory Macrophage Differentiation but also Limits It through Suppression of NFATc1 Expression

  2015cites this paper
• Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment.

  2015cites this paper